Mitochondrial
Elamipretide (SS-31)
SS-31 / MTP-131 / Forzinity
- Peptide length
- 4 amino acids
Modified tetrapeptide
Research contextDefined therapeutic evidence
Read the linked studies for their methods and limitations.
A mitochondria-targeted peptide. FDA granted Forzinity accelerated approval in 2025 to improve muscle strength in patients with Barth syndrome weighing at least 30 kg.
- Family
- Mitochondria-targeted peptide
- Research frame
- Cardiolipin-associated mitochondrial membrane
- Molecular format
- Modified tetrapeptide
Read the evidence
Accelerated approval used an intermediate clinical endpoint and requires confirmation of benefit. It does not establish broad anti-aging or exercise benefits.
Resolve the identity
Distinguish the regulated elamipretide product from research preparations labeled SS-31 and preserve its modified-residue stereochemistry.